On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE:NVS) for its PTC518 Huntington’s disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales. Also Read…

Benzinga

New York

United States

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program - PTC Therapeutics (NASDAQ:PTCT), Novartis (NYSE:NVS)

Ad Fontes Media

Media Bias/Fact Check

A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa Health Care researchers.

Medical Xpress

Common heart drug may slow progression of Huntington's disease

News Medical

Ian Birkby

Beta-blocker drugs may slow Huntington's disease progression

RBC Capital has upgraded PTC Therapeutics (PTCT) to outperform from sector perform on the company’s deal with Novartis (NVS) for its Huntington’s disease program. Read more here.

Seeking Alpha

PTC upgraded to outperform by RBC on Novartis deal (NASDAQ:PTCT)

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. The post PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone appeared first on Investor's Business Daily.

All Sides

Investor's Business Daily

How A $2.9 Billion Deal Sent This Biotech To The Stratosphere

Novartis, which has previously tried to develop a Huntington's treatment, is licensing an experimental drug from PTC.

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

Novartis to pay $1 billion upfront to license Huntington's drug from PTC

Novartis is securing global rights to a PTC Therapeutics Huntington’s disease drug candidate that has encouraging Phase 2 data that will be discussed with the FDA to plan a pivotal study. Last year, Novartis discontinued its Huntington’s program after safety issues emerged in Phase 2 testing.  The post Novartis Tries Again in Huntington’s, Putting Up $1B to Partner on a PTC Therapeutics Drug appeared first on MedCity News.

MedCity News

Novartis Tries Again in Huntington’s, Putting Up $1B to Partner on a PTC Therapeutics Drug

– PTC to receive $1.0B in cash at closing – – PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones – – PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales – – Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study – – PTC will host a conference call on Dec. 2, 2024, at …

pipelinereview

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program - Pipelinereview

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read PTC Therapeutics’s 8K filing here. About PTC Therapeutics (Get Free Report) PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in […]

tickerreport.com

PTC Therapeutics Signs License and Collaboration Agreement with Novartis for PTC518 Huntington’s Disease ProgramWARREN, N.J., Dec. 2, 2024 – In a strategic move, PTC Therapeutics, Inc. (NASDAQ: PTCT) disclosed today the successful negotiation of an e

By Mariam Sunny (Reuters) –     Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics’ promising experimental drug for a neurological disorder called Huntington’s disease, sending the U.S.-based biotech’s shares up about 14% on Monday. The drug, code-named “PTC518,” is being tested in a mid-stage study for the rare disorder that affects about 30,000 people in the U.S.  Earlier this year, interim 12-month data from a mid-stage…

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program - PTC Therapeutics (NASDAQ:PTCT), Novartis (NYSE:NVS)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics